PE20171320A1 - Analogos de calcitonina para tratar enfermedades y trastornos - Google Patents

Analogos de calcitonina para tratar enfermedades y trastornos

Info

Publication number
PE20171320A1
PE20171320A1 PE2017001166A PE2017001166A PE20171320A1 PE 20171320 A1 PE20171320 A1 PE 20171320A1 PE 2017001166 A PE2017001166 A PE 2017001166A PE 2017001166 A PE2017001166 A PE 2017001166A PE 20171320 A1 PE20171320 A1 PE 20171320A1
Authority
PE
Peru
Prior art keywords
disorders
treat diseases
seq
calcitonin analogs
calcitonin
Prior art date
Application number
PE2017001166A
Other languages
English (en)
Inventor
Morten Karsdal
Kim Henriksen
Kim Vietz Andreassen
Sofie Gydesen
Sara Toftegaard Hjuler
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of PE20171320A1 publication Critical patent/PE20171320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a un analogo de calcitonina que comprende peptidos con una secuencia de aminoacidos tales como SEC ID NO: 1, SEC ID NO:2, SEC ID NO: 3, SEC ID NO: 4, entre otros. Tambien se refiere a un metodo de tratamiento. Dicho analogo es util en la disminucion de los trigliceridos o grasa acumulados en el higado.
PE2017001166A 2015-01-08 2016-01-07 Analogos de calcitonina para tratar enfermedades y trastornos PE20171320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1500263.7A GB201500263D0 (en) 2015-01-08 2015-01-08 Calcitonin analogues for treating diseases and disorders

Publications (1)

Publication Number Publication Date
PE20171320A1 true PE20171320A1 (es) 2017-09-07

Family

ID=52597359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001166A PE20171320A1 (es) 2015-01-08 2016-01-07 Analogos de calcitonina para tratar enfermedades y trastornos

Country Status (17)

Country Link
US (2) US10350272B2 (es)
EP (1) EP3247383A1 (es)
JP (1) JP2018502854A (es)
KR (1) KR20170120576A (es)
CN (1) CN107206056A (es)
AU (1) AU2016205994A1 (es)
BR (1) BR112017014552A2 (es)
CA (1) CA2969293A1 (es)
CL (1) CL2017001773A1 (es)
CO (1) CO2017007007A2 (es)
EA (1) EA201791154A1 (es)
GB (1) GB201500263D0 (es)
IL (1) IL253026A0 (es)
MX (1) MX2017008755A (es)
PE (1) PE20171320A1 (es)
PH (1) PH12017500988A1 (es)
WO (1) WO2016110525A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) * 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1137431A1 (en) 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
WO2004084870A1 (en) 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
CN1856321B (zh) 2003-07-23 2012-10-03 诺瓦提斯公司 降钙素在骨关节炎中的用途
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
US20080200563A1 (en) 2004-07-22 2008-08-21 Thiomatrix Forschungs- Und Beratungs- Gmbh Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
CA2613471C (en) 2005-06-24 2016-09-06 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EP1834635B1 (en) 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Stable nanocapsule systems for the administration of active molecules
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
AU2012332265B2 (en) * 2011-11-02 2016-11-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
EP3321278B1 (en) * 2013-11-14 2019-01-09 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders

Also Published As

Publication number Publication date
AU2016205994A1 (en) 2017-06-15
CL2017001773A1 (es) 2018-03-09
US10350272B2 (en) 2019-07-16
WO2016110525A1 (en) 2016-07-14
EA201791154A1 (ru) 2017-09-29
CN107206056A (zh) 2017-09-26
GB201500263D0 (en) 2015-02-25
PH12017500988A1 (en) 2017-12-18
US20190328843A1 (en) 2019-10-31
IL253026A0 (en) 2017-08-31
CA2969293A1 (en) 2016-07-14
JP2018502854A (ja) 2018-02-01
BR112017014552A2 (pt) 2018-05-15
MX2017008755A (es) 2017-11-17
CO2017007007A2 (es) 2018-01-31
EP3247383A1 (en) 2017-11-29
KR20170120576A (ko) 2017-10-31
US20180264085A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY36550A (es) Oligómeros antisentido de tau y sus usos
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
ECSP17056415A (es) Anticuerpos contra tau y sus usos
EA201690606A1 (ru) Аналоги глюкагона
PE20180128A1 (es) Compuestos antisenescentes y usos de los mismos
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
PE20171320A1 (es) Analogos de calcitonina para tratar enfermedades y trastornos
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
CO2019006443A2 (es) Peptido para tratar degeneracion macular relacionada con la edad
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
BR112016028561A8 (pt) composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
NI201700026A (es) Compuestos dipeptidil cetoamídicos y su uso para el tratamiento y/o la prevención de la acumulación de grasa.
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
AR118705A2 (es) Polipéptido del factor vii para tratar enfermedades, método para prepararlo y composición que lo contiene
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina